| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 73 | 2026 | 1836 | 10.410 |
Why?
|
| Radiotherapy, Intensity-Modulated | 24 | 2026 | 200 | 5.020 |
Why?
|
| Androgen Antagonists | 22 | 2026 | 157 | 3.870 |
Why?
|
| Radiation Injuries | 10 | 2026 | 160 | 3.720 |
Why?
|
| Prostatectomy | 27 | 2026 | 490 | 3.540 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2026 | 1535 | 2.770 |
Why?
|
| Salvage Therapy | 18 | 2026 | 239 | 2.580 |
Why?
|
| Prostate-Specific Antigen | 26 | 2026 | 354 | 2.490 |
Why?
|
| Anus Neoplasms | 5 | 2022 | 41 | 2.460 |
Why?
|
| Adenocarcinoma | 17 | 2019 | 1211 | 2.440 |
Why?
|
| Radiotherapy Dosage | 29 | 2025 | 479 | 2.400 |
Why?
|
| Chemoradiotherapy | 7 | 2021 | 337 | 2.280 |
Why?
|
| Radiotherapy, Image-Guided | 6 | 2025 | 66 | 1.930 |
Why?
|
| Quality of Life | 9 | 2026 | 1895 | 1.900 |
Why?
|
| Radiosurgery | 7 | 2025 | 351 | 1.750 |
Why?
|
| Rectal Neoplasms | 6 | 2026 | 138 | 1.740 |
Why?
|
| Radiotherapy, Conformal | 7 | 2016 | 88 | 1.670 |
Why?
|
| Aged | 69 | 2026 | 21758 | 1.580 |
Why?
|
| Male | 101 | 2026 | 47076 | 1.480 |
Why?
|
| Fiducial Markers | 3 | 2025 | 12 | 1.460 |
Why?
|
| Aged, 80 and over | 37 | 2025 | 7389 | 1.450 |
Why?
|
| Urinary Incontinence | 4 | 2016 | 225 | 1.430 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2018 | 323 | 1.410 |
Why?
|
| Anticoagulants | 5 | 2022 | 486 | 1.370 |
Why?
|
| Middle Aged | 71 | 2026 | 29428 | 1.370 |
Why?
|
| Follow-Up Studies | 24 | 2026 | 4025 | 1.340 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2024 | 401 | 1.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2024 | 159 | 1.210 |
Why?
|
| Humans | 122 | 2026 | 98080 | 1.210 |
Why?
|
| Prostate | 7 | 2023 | 434 | 1.100 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2026 | 336 | 1.080 |
Why?
|
| Brachytherapy | 9 | 2025 | 139 | 1.080 |
Why?
|
| Head and Neck Neoplasms | 6 | 2021 | 1088 | 1.050 |
Why?
|
| Neoplasm Staging | 23 | 2023 | 2080 | 1.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2025 | 216 | 1.010 |
Why?
|
| Combined Modality Therapy | 23 | 2026 | 1751 | 0.990 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2025 | 2666 | 0.950 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 310 | 0.950 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2025 | 384 | 0.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2026 | 2658 | 0.920 |
Why?
|
| Radiotherapy | 9 | 2019 | 325 | 0.910 |
Why?
|
| Fluorouracil | 7 | 2017 | 541 | 0.910 |
Why?
|
| Urogenital System | 4 | 2014 | 11 | 0.900 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2024 | 100 | 0.880 |
Why?
|
| Capecitabine | 5 | 2024 | 103 | 0.870 |
Why?
|
| Kidney Neoplasms | 4 | 2025 | 556 | 0.850 |
Why?
|
| Treatment Outcome | 28 | 2026 | 9711 | 0.840 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.830 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 450 | 0.810 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2022 | 194 | 0.780 |
Why?
|
| Rectal Diseases | 3 | 2013 | 25 | 0.770 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 831 | 0.770 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2018 | 246 | 0.750 |
Why?
|
| Cooperative Behavior | 1 | 2023 | 199 | 0.720 |
Why?
|
| Prospective Studies | 10 | 2026 | 4823 | 0.710 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2026 | 3606 | 0.700 |
Why?
|
| Organs at Risk | 4 | 2025 | 56 | 0.700 |
Why?
|
| Radiation Oncology | 4 | 2021 | 130 | 0.700 |
Why?
|
| Aspirin | 2 | 2013 | 169 | 0.680 |
Why?
|
| Gastrointestinal Tract | 3 | 2013 | 198 | 0.680 |
Why?
|
| Pancreatic Neoplasms | 4 | 2017 | 769 | 0.660 |
Why?
|
| Patient Care Team | 1 | 2023 | 320 | 0.650 |
Why?
|
| Urinary Bladder | 3 | 2024 | 261 | 0.650 |
Why?
|
| Risk Assessment | 12 | 2020 | 2585 | 0.640 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2017 | 41 | 0.630 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2018 | 1105 | 0.630 |
Why?
|
| Cystectomy | 4 | 2024 | 124 | 0.630 |
Why?
|
| Hypersensitivity | 1 | 2022 | 166 | 0.620 |
Why?
|
| Long Term Adverse Effects | 1 | 2019 | 7 | 0.600 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 152 | 0.590 |
Why?
|
| Analysis of Variance | 9 | 2015 | 889 | 0.590 |
Why?
|
| Rectum | 4 | 2014 | 150 | 0.590 |
Why?
|
| Retrospective Studies | 26 | 2026 | 10973 | 0.580 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 238 | 0.570 |
Why?
|
| Hematuria | 3 | 2022 | 51 | 0.570 |
Why?
|
| Prognosis | 16 | 2024 | 4116 | 0.570 |
Why?
|
| Neoplasm Grading | 9 | 2022 | 422 | 0.560 |
Why?
|
| Cohort Studies | 9 | 2025 | 3212 | 0.560 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2025 | 1302 | 0.560 |
Why?
|
| Adult | 33 | 2025 | 29539 | 0.560 |
Why?
|
| Neoadjuvant Therapy | 4 | 2026 | 478 | 0.550 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 82 | 0.520 |
Why?
|
| Time Factors | 15 | 2020 | 5567 | 0.510 |
Why?
|
| Leukopenia | 1 | 2016 | 66 | 0.490 |
Why?
|
| Organ Transplantation | 1 | 2020 | 306 | 0.490 |
Why?
|
| Pelvic Bones | 1 | 2016 | 46 | 0.480 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2015 | 525 | 0.460 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 194 | 0.450 |
Why?
|
| Risk Factors | 10 | 2020 | 6233 | 0.450 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1013 | 0.450 |
Why?
|
| Bone Marrow | 1 | 2016 | 418 | 0.430 |
Why?
|
| Sexuality | 1 | 2014 | 40 | 0.420 |
Why?
|
| Biomarkers, Tumor | 3 | 2012 | 1764 | 0.420 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 1009 | 0.420 |
Why?
|
| Tumor Burden | 5 | 2019 | 333 | 0.420 |
Why?
|
| Lymphatic Metastasis | 6 | 2024 | 520 | 0.390 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2013 | 244 | 0.390 |
Why?
|
| Survival Rate | 9 | 2019 | 2041 | 0.390 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 2373 | 0.390 |
Why?
|
| Urinary Retention | 2 | 2010 | 43 | 0.390 |
Why?
|
| Transurethral Resection of Prostate | 2 | 2010 | 10 | 0.380 |
Why?
|
| Herpes Zoster | 1 | 2013 | 26 | 0.380 |
Why?
|
| CA-19-9 Antigen | 1 | 2012 | 14 | 0.370 |
Why?
|
| Hospitalization | 1 | 2018 | 991 | 0.370 |
Why?
|
| SEER Program | 6 | 2020 | 243 | 0.360 |
Why?
|
| Chemoprevention | 1 | 2012 | 93 | 0.360 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 40 | 0.360 |
Why?
|
| Portal Vein | 1 | 2012 | 121 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2017 | 903 | 0.350 |
Why?
|
| Diabetes Complications | 1 | 2013 | 176 | 0.350 |
Why?
|
| Risk | 4 | 2020 | 660 | 0.350 |
Why?
|
| Radioimmunodetection | 2 | 2008 | 12 | 0.340 |
Why?
|
| Postoperative Complications | 2 | 2020 | 2681 | 0.340 |
Why?
|
| Deoxycytidine | 2 | 2012 | 217 | 0.340 |
Why?
|
| Neoplasm Metastasis | 4 | 2025 | 1089 | 0.330 |
Why?
|
| Prostatism | 1 | 2010 | 5 | 0.320 |
Why?
|
| Female | 26 | 2026 | 51536 | 0.320 |
Why?
|
| Lymph Nodes | 3 | 2020 | 560 | 0.320 |
Why?
|
| Urination Disorders | 1 | 2010 | 52 | 0.310 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 112 | 0.310 |
Why?
|
| Body Burden | 1 | 2009 | 10 | 0.310 |
Why?
|
| Venous Thrombosis | 1 | 2012 | 264 | 0.300 |
Why?
|
| Withholding Treatment | 1 | 2010 | 131 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1110 | 0.300 |
Why?
|
| Survival Analysis | 9 | 2019 | 1527 | 0.290 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2016 | 193 | 0.290 |
Why?
|
| Smoking | 1 | 2013 | 674 | 0.280 |
Why?
|
| Leucovorin | 3 | 2017 | 205 | 0.280 |
Why?
|
| Models, Statistical | 1 | 2012 | 601 | 0.280 |
Why?
|
| Comorbidity | 3 | 2021 | 1033 | 0.270 |
Why?
|
| Pelvis | 2 | 2026 | 106 | 0.260 |
Why?
|
| Hemorrhage | 1 | 2009 | 299 | 0.250 |
Why?
|
| Ganglioglioma | 1 | 2006 | 9 | 0.250 |
Why?
|
| Disease Progression | 3 | 2020 | 1610 | 0.250 |
Why?
|
| Neoplasm, Residual | 4 | 2026 | 206 | 0.240 |
Why?
|
| Disease-Free Survival | 7 | 2014 | 1193 | 0.240 |
Why?
|
| Treatment Failure | 4 | 2016 | 300 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 403 | 0.240 |
Why?
|
| Carcinoma | 2 | 2012 | 440 | 0.240 |
Why?
|
| Testicular Neoplasms | 2 | 2019 | 126 | 0.240 |
Why?
|
| Abdomen | 1 | 2006 | 120 | 0.230 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2006 | 96 | 0.230 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2025 | 107 | 0.230 |
Why?
|
| Postoperative Period | 3 | 2015 | 321 | 0.230 |
Why?
|
| Disease Management | 3 | 2024 | 377 | 0.220 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 922 | 0.210 |
Why?
|
| United States | 7 | 2021 | 8197 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 262 | 0.210 |
Why?
|
| Leuprolide | 1 | 2024 | 34 | 0.210 |
Why?
|
| Probability | 3 | 2012 | 356 | 0.210 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 244 | 0.210 |
Why?
|
| Urethral Neoplasms | 2 | 2018 | 10 | 0.200 |
Why?
|
| Motion | 1 | 2023 | 96 | 0.190 |
Why?
|
| Patient Selection | 3 | 2017 | 726 | 0.190 |
Why?
|
| Phenylthiohydantoin | 2 | 2022 | 57 | 0.190 |
Why?
|
| Contrast Media | 2 | 2016 | 1011 | 0.180 |
Why?
|
| Ipilimumab | 1 | 2022 | 68 | 0.180 |
Why?
|
| Propensity Score | 2 | 2020 | 213 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2025 | 977 | 0.180 |
Why?
|
| Severity of Illness Index | 4 | 2013 | 2013 | 0.170 |
Why?
|
| Radiation Oncologists | 2 | 2021 | 15 | 0.170 |
Why?
|
| Incidence | 2 | 2022 | 1779 | 0.170 |
Why?
|
| Ticlopidine | 2 | 2012 | 25 | 0.170 |
Why?
|
| Radium | 1 | 2020 | 7 | 0.160 |
Why?
|
| Oncologists | 1 | 2021 | 43 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2006 | 839 | 0.160 |
Why?
|
| Warfarin | 2 | 2012 | 108 | 0.160 |
Why?
|
| Platelet Count | 1 | 2020 | 94 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 4 | 2024 | 582 | 0.150 |
Why?
|
| Internship and Residency | 2 | 2021 | 1123 | 0.150 |
Why?
|
| Radiologic Health | 1 | 2019 | 2 | 0.150 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 20 | 0.150 |
Why?
|
| Sezary Syndrome | 1 | 2019 | 12 | 0.150 |
Why?
|
| Depsipeptides | 1 | 2019 | 30 | 0.150 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 30 | 0.140 |
Why?
|
| Electrons | 1 | 2019 | 52 | 0.140 |
Why?
|
| Mitomycin | 2 | 2016 | 30 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2021 | 801 | 0.140 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 89 | 0.140 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 388 | 0.140 |
Why?
|
| Proctoscopy | 1 | 2017 | 1 | 0.130 |
Why?
|
| Prostatic Diseases | 1 | 2017 | 2 | 0.130 |
Why?
|
| Digital Rectal Examination | 1 | 2017 | 5 | 0.130 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 127 | 0.130 |
Why?
|
| Movement | 1 | 2020 | 313 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 1103 | 0.130 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 117 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 95 | 0.130 |
Why?
|
| Clinical Competence | 3 | 2021 | 865 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 3022 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 492 | 0.130 |
Why?
|
| Neoplasms | 1 | 2013 | 3334 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 1945 | 0.130 |
Why?
|
| Medicare | 1 | 2020 | 467 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 158 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2018 | 236 | 0.120 |
Why?
|
| Nephrectomy | 1 | 2019 | 290 | 0.120 |
Why?
|
| Camptothecin | 1 | 2017 | 198 | 0.120 |
Why?
|
| Remission Induction | 1 | 2018 | 754 | 0.120 |
Why?
|
| Internationality | 1 | 2016 | 79 | 0.120 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 52 | 0.120 |
Why?
|
| Ilium | 1 | 2016 | 32 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 2784 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2022 | 819 | 0.120 |
Why?
|
| Neutropenia | 1 | 2016 | 211 | 0.120 |
Why?
|
| Patient Safety | 1 | 2018 | 235 | 0.120 |
Why?
|
| Urology | 1 | 2017 | 144 | 0.110 |
Why?
|
| Software | 1 | 2020 | 693 | 0.110 |
Why?
|
| Seminoma | 1 | 2015 | 15 | 0.110 |
Why?
|
| Orchiectomy | 1 | 2015 | 64 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 839 | 0.110 |
Why?
|
| Transcriptome | 1 | 2021 | 820 | 0.110 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2014 | 30 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 520 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 63 | 0.110 |
Why?
|
| Carboplatin | 1 | 2015 | 331 | 0.100 |
Why?
|
| Kidney | 1 | 2019 | 1123 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 254 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 638 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 449 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 36 | 0.100 |
Why?
|
| Radiography | 2 | 2006 | 764 | 0.100 |
Why?
|
| Metalloporphyrins | 1 | 2012 | 26 | 0.090 |
Why?
|
| Enoxaparin | 1 | 2012 | 27 | 0.090 |
Why?
|
| Prevalence | 1 | 2016 | 1384 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2013 | 211 | 0.090 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2013 | 89 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 467 | 0.090 |
Why?
|
| Age Factors | 3 | 2010 | 1962 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2017 | 578 | 0.090 |
Why?
|
| Curriculum | 1 | 2016 | 633 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2012 | 426 | 0.080 |
Why?
|
| Proctitis | 1 | 2010 | 12 | 0.080 |
Why?
|
| Students, Medical | 1 | 2016 | 449 | 0.080 |
Why?
|
| Neck Dissection | 2 | 2008 | 67 | 0.080 |
Why?
|
| Algorithms | 2 | 2019 | 2002 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1284 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2014 | 319 | 0.080 |
Why?
|
| Nitriles | 2 | 2022 | 171 | 0.080 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2010 | 43 | 0.080 |
Why?
|
| Seminal Vesicles | 2 | 2016 | 40 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2013 | 369 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2012 | 373 | 0.080 |
Why?
|
| Benzamides | 2 | 2022 | 260 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2006 | 1782 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 3272 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 707 | 0.070 |
Why?
|
| Urologic Diseases | 1 | 2009 | 38 | 0.070 |
Why?
|
| Thymidine Phosphorylase | 1 | 2008 | 4 | 0.070 |
Why?
|
| Registries | 3 | 2010 | 1122 | 0.070 |
Why?
|
| Vitamin B Complex | 1 | 2008 | 22 | 0.070 |
Why?
|
| Acute Disease | 1 | 2010 | 860 | 0.070 |
Why?
|
| Indium Radioisotopes | 1 | 2007 | 9 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 7507 | 0.060 |
Why?
|
| Pharynx | 1 | 2006 | 43 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2026 | 4 | 0.060 |
Why?
|
| Abiraterone Acetate | 1 | 2026 | 14 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2006 | 145 | 0.060 |
Why?
|
| Cisplatin | 2 | 2024 | 578 | 0.060 |
Why?
|
| Recurrence | 1 | 2009 | 1254 | 0.060 |
Why?
|
| Prednisone | 1 | 2026 | 251 | 0.060 |
Why?
|
| Re-Irradiation | 1 | 2025 | 18 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 412 | 0.050 |
Why?
|
| Chicago | 1 | 2009 | 1513 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 75 | 0.050 |
Why?
|
| Palliative Care | 1 | 2006 | 290 | 0.050 |
Why?
|
| Digestive System | 1 | 2003 | 42 | 0.050 |
Why?
|
| Guanidines | 1 | 2022 | 34 | 0.050 |
Why?
|
| Physics | 1 | 2021 | 21 | 0.040 |
Why?
|
| Mastectomy | 1 | 2004 | 271 | 0.040 |
Why?
|
| Androgens | 1 | 2021 | 164 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2021 | 92 | 0.040 |
Why?
|
| Piperazines | 1 | 2022 | 306 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 187 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 518 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 304 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 107 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2006 | 4001 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 209 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 200 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 168 | 0.030 |
Why?
|
| Aftercare | 1 | 2019 | 91 | 0.030 |
Why?
|
| Kallikreins | 1 | 2017 | 47 | 0.030 |
Why?
|
| Efficiency | 1 | 2017 | 39 | 0.030 |
Why?
|
| Inflammation | 1 | 2004 | 1120 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2017 | 181 | 0.030 |
Why?
|
| Radiometry | 1 | 2016 | 64 | 0.030 |
Why?
|
| Job Satisfaction | 1 | 2017 | 86 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 425 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 126 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 130 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 136 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 360 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 186 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 726 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1782 | 0.030 |
Why?
|
| Child | 1 | 2006 | 7681 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1012 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 217 | 0.030 |
Why?
|
| Internet | 1 | 2017 | 358 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 241 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 102 | 0.030 |
Why?
|
| Adolescent | 1 | 2006 | 10080 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 187 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1094 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1646 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 532 | 0.020 |
Why?
|
| Nomograms | 1 | 2007 | 34 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2007 | 231 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1995 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1129 | 0.010 |
Why?
|